These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 39237765)

  • 21. Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
    Kozakai Y; Kamada R; Kiyota Y; Yoshimura F; Tanino K; Sakaguchi K
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5593-5596. PubMed ID: 25466181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
    Zhang M; Xu E; Zhang J; Chen X
    Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D.
    Chuman Y; Yagi H; Fukuda T; Nomura T; Matsukizono M; Shimohigashi Y; Sakaguchi K
    Protein Pept Lett; 2008; 15(9):938-48. PubMed ID: 18991770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogene-induced senescence pathways weave an intricate tapestry.
    Yaswen P; Campisi J
    Cell; 2007 Jan; 128(2):233-4. PubMed ID: 17254959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.
    Khadka P; Reitman ZJ; Lu S; Buchan G; Gionet G; Dubois F; Carvalho DM; Shih J; Zhang S; Greenwald NF; Zack T; Shapira O; Pelton K; Hartley R; Bear H; Georgis Y; Jarmale S; Melanson R; Bonanno K; Schoolcraft K; Miller PG; Condurat AL; Gonzalez EM; Qian K; Morin E; Langhnoja J; Lupien LE; Rendo V; Digiacomo J; Wang D; Zhou K; Kumbhani R; Guerra Garcia ME; Sinai CE; Becker S; Schneider R; Vogelzang J; Krug K; Goodale A; Abid T; Kalani Z; Piccioni F; Beroukhim R; Persky NS; Root DE; Carcaboso AM; Ebert BL; Fuller C; Babur O; Kieran MW; Jones C; Keshishian H; Ligon KL; Carr SA; Phoenix TN; Bandopadhayay P
    Nat Commun; 2022 Feb; 13(1):604. PubMed ID: 35105861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
    Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
    Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crystal structure and mechanistic studies of the PPM1D serine/threonine phosphatase catalytic domain.
    Kumar JP; Kosek D; Durell SR; Miller Jenkins LM; Debnath S; Coussens NP; Hall MD; Appella DH; Dyda F; Mazur SJ; Appella E
    J Biol Chem; 2024 Aug; 300(8):107561. PubMed ID: 39002674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
    Yagi H; Chuman Y; Kozakai Y; Imagawa T; Takahashi Y; Yoshimura F; Tanino K; Sakaguchi K
    Bioorg Med Chem Lett; 2012 Jan; 22(1):729-32. PubMed ID: 22115592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
    Lu ZW; Wen D; Wei WJ; Han LT; Xiang J; Wang YL; Wang Y; Liao T; Ji QH
    Oncol Rep; 2020 Mar; 43(3):783-794. PubMed ID: 31922231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
    Ali AY; Abedini MR; Tsang BK
    Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
    Zhang L; Chen LH; Wan H; Yang R; Wang Z; Feng J; Yang S; Jones S; Wang S; Zhou W; Zhu H; Killela PJ; Zhang J; Wu Z; Li G; Hao S; Wang Y; Webb JB; Friedman HS; Friedman AH; McLendon RE; He Y; Reitman ZJ; Bigner DD; Yan H
    Nat Genet; 2014 Jul; 46(7):726-30. PubMed ID: 24880341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome.
    Jansen S; Geuer S; Pfundt R; Brough R; Ghongane P; Herkert JC; Marco EJ; Willemsen MH; Kleefstra T; Hannibal M; Shieh JT; Lynch SA; Flinter F; FitzPatrick DR; Gardham A; Bernhard B; Ragge N; Newbury-Ecob R; Bernier R; Kvarnung M; Magnusson EA; Wessels MW; van Slegtenhorst MA; Monaghan KG; de Vries P; Veltman JA; ; Lord CJ; Vissers LE; de Vries BB
    Am J Hum Genet; 2017 Apr; 100(4):650-658. PubMed ID: 28343630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair.
    Lu X; Bocangel D; Nannenga B; Yamaguchi H; Appella E; Donehower LA
    Mol Cell; 2004 Aug; 15(4):621-34. PubMed ID: 15327777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDK2 transcriptional repression is an essential effector in p53-dependent cellular senescence-implications for therapeutic intervention.
    Zalzali H; Nasr B; Harajly M; Basma H; Ghamloush F; Ghayad S; Ghanem N; Evan GI; Saab R
    Mol Cancer Res; 2015 Jan; 13(1):29-40. PubMed ID: 25149358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function.
    Proia DA; Nannenga BW; Donehower LA; Weigel NL
    J Biol Chem; 2006 Mar; 281(11):7089-101. PubMed ID: 16352595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-regulation of wild-type p53-induced phosphatase 1 (Wip1) plays a critical role in regulating several p53-dependent functions in premature senescent tumor cells.
    Crescenzi E; Raia Z; Pacifico F; Mellone S; Moscato F; Palumbo G; Leonardi A
    J Biol Chem; 2013 Jun; 288(23):16212-16224. PubMed ID: 23612976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
    Pärssinen J; Alarmo EL; Karhu R; Kallioniemi A
    Cancer Genet Cytogenet; 2008 Apr; 182(1):33-9. PubMed ID: 18328948
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Kahn JD; Miller PG; Silver AJ; Sellar RS; Bhatt S; Gibson C; McConkey M; Adams D; Mar B; Mertins P; Fereshetian S; Krug K; Zhu H; Letai A; Carr SA; Doench J; Jaiswal S; Ebert BL
    Blood; 2018 Sep; 132(11):1095-1105. PubMed ID: 29954749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
    Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
    Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.